NextWave Pharmaceuticals

Pfizer Acquires NextWave Pharmaceuticals

The acquisition includes North American commercialization rights to recently approved Quillivant XR, an ADHD treatment.

Pfizer Inc. today announced that it has completed its acquisition of NextWave Pharmaceuticals, Inc., a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).

No votes yet
Syndicate content